GENMAB A/S -SP ADR (GMAB)

US3723032062 - ADR

27.05  +0.81 (+3.09%)

After market: 27.05 0 (0%)

News Image
12 days ago - Chartmill

NASDAQ:GMAB, an undervalued stock with good fundamentals.

GENMAB A/S -SP ADR (NASDAQ:GMAB) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

News Image
18 days ago - Market News Video

Genmab is Now Oversold (GMAB)

News Image
18 days ago - InvestorPlace

7 Biotech Stocks to Buy on the Dip: June 2024

With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation.

News Image
a month ago - InvestorPlace

7 Stocks That Could Safely 10X by 2030

Unlock the potential for exponential growth with these seven 10x stocks that could skyrocket by 2030 if the stars align.

News Image
2 months ago - InvestorPlace

7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

News Image
2 months ago - InvestorPlace

GMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Image
3 months ago - Investor's Business Daily

Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

News Image
3 months ago - Investor's Business Daily

Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image
5 months ago - Seeking Alpha

AbbVie/ Genmab win FDA priority review for lymphoma therapy (NYSE:ABBV)

Genmab (GMAB) and AbbVie (ABBV) win FDA priority review for a marketing application to expand the label for their bispecific antibody epcoritamab-bysp. Read more here.

News Image
5 months ago - Seeking Alpha

BMO upgrades Genmab to outperform, cites diversification potential (NASDAQ:GMAB)

BMO has upgraded Genmab (GMAB) to outperform, stating that it was “incrementally more confident” in the company’s ability to diversify its business longer term